SG10201702951RA - Viral inactivation during purification of antibodies - Google Patents
Viral inactivation during purification of antibodiesInfo
- Publication number
- SG10201702951RA SG10201702951RA SG10201702951RA SG10201702951RA SG10201702951RA SG 10201702951R A SG10201702951R A SG 10201702951RA SG 10201702951R A SG10201702951R A SG 10201702951RA SG 10201702951R A SG10201702951R A SG 10201702951RA SG 10201702951R A SG10201702951R A SG 10201702951RA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- during purification
- viral inactivation
- inactivation during
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19675408P | 2008-10-20 | 2008-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201702951RA true SG10201702951RA (en) | 2017-06-29 |
Family
ID=41832791
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201702951RA SG10201702951RA (en) | 2008-10-20 | 2009-10-20 | Viral inactivation during purification of antibodies |
SG2013077995A SG195577A1 (en) | 2008-10-20 | 2009-10-20 | Viral inactivation during purification of antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013077995A SG195577A1 (en) | 2008-10-20 | 2009-10-20 | Viral inactivation during purification of antibodies |
Country Status (16)
Country | Link |
---|---|
US (2) | US9109010B2 (en) |
EP (1) | EP2346897A2 (en) |
JP (3) | JP5856845B2 (en) |
KR (1) | KR101722423B1 (en) |
CN (2) | CN102257005A (en) |
AU (1) | AU2009307737B2 (en) |
BR (1) | BRPI0920572A8 (en) |
CA (1) | CA2738499A1 (en) |
IL (1) | IL211917A0 (en) |
MX (1) | MX2011004201A (en) |
NZ (1) | NZ592097A (en) |
RU (1) | RU2551237C2 (en) |
SG (2) | SG10201702951RA (en) |
TW (1) | TW201028433A (en) |
WO (1) | WO2010048192A2 (en) |
ZA (1) | ZA201102552B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2535734T3 (en) | 2008-10-20 | 2015-05-14 | Abbvie Inc. | Isolation and purification of antibodies by affinity chromatography with protein A |
TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
CN107188960A (en) * | 2009-08-07 | 2017-09-22 | Emd密理博公司 | The method of target protein from one or more impurity of sample |
EP3037104B1 (en) | 2009-10-20 | 2020-05-27 | AbbVie Inc. | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
EP2598223B1 (en) | 2010-07-30 | 2022-04-06 | EMD Millipore Corporation | Chromatography media and method |
CN103379949B (en) * | 2010-10-11 | 2016-09-14 | 艾伯维巴哈马有限公司 | Method for purifying proteins |
CA2814781A1 (en) * | 2010-11-01 | 2012-05-10 | Diderik Reinder Kremer | Single unit ion exchange chromatography antibody purification |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
KR20140004231A (en) * | 2011-07-08 | 2014-01-10 | 이엠디 밀리포어 코포레이션 | Improved depth filters for disposable biotechnological processes |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
WO2014004103A1 (en) * | 2012-06-29 | 2014-01-03 | Emd Millipore Corporation | Methods for inactivating viruses during a protein purification process |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
BR112015009969A2 (en) * | 2012-11-05 | 2017-07-11 | Medimmune Llc | synagis® isolation method in the absence of benzonase |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
JP2016519145A (en) * | 2013-05-15 | 2016-06-30 | メディミューン リミテッド | Purification of recombinantly produced polypeptides |
KR101569783B1 (en) * | 2013-06-05 | 2015-11-19 | 한화케미칼 주식회사 | A Method of Antibody Purification |
JP6549126B2 (en) | 2013-09-10 | 2019-07-31 | モックヴィー ソリューションズ, インコーポレイテッド | Methods and kits for quantifying the removal of mock viral particles from a generated solution |
CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
EP3683232A1 (en) | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
MX2016004926A (en) | 2013-10-16 | 2017-01-18 | Oncobiologics Inc | Buffer formulations for enhanced antibody stability. |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
SG11201605256YA (en) * | 2013-12-27 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Method for purifying antibody having low isoelectric point |
EP3137186B1 (en) | 2014-04-30 | 2021-01-27 | Novo Nordisk A/S | Methods for the purification of proteins using caprylic acid |
JP2017519734A (en) * | 2014-05-28 | 2017-07-20 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | Virus reduction method |
CN106794389A (en) | 2014-09-02 | 2017-05-31 | Emd密理博公司 | High surface area fiber medium with nanometer fibrillated surface feature |
TW201628649A (en) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | Process for reducing subvisible particles in a pharmaceutical formulation |
JP6665184B2 (en) | 2014-12-08 | 2020-03-13 | イー・エム・デイー・ミリポア・コーポレイシヨン | Mixed bed ion exchange adsorbent |
EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
EP3088006A1 (en) * | 2015-04-28 | 2016-11-02 | Bayer Technology Services GmbH | Method for continuous viral inactivation in a microreactor |
SG11201803989WA (en) * | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
MX2018009341A (en) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Buffer formulations for enhanced antibody stability. |
CN107586760B (en) * | 2016-07-07 | 2019-10-11 | 扬州优邦生物药品有限公司 | A kind of purification process of 2 porcine circovirus virus-like particle and its application |
BR112019000872A2 (en) | 2016-08-16 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | methods for quantifying individual antibodies in a mixture |
SG11201902667UA (en) | 2016-10-25 | 2019-05-30 | Regeneron Pharma | Methods and systems for chromatography data analysis |
EP3446710A1 (en) | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
CN108059650A (en) * | 2018-01-05 | 2018-05-22 | 上海药明生物技术有限公司 | Purification process in low pH virus inactivation technologies |
TW202005694A (en) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | Systems and methods for preparing a polypeptide from a mixture |
EP4090668A1 (en) * | 2020-01-17 | 2022-11-23 | Regeneron Pharmaceuticals, Inc. | Hydrophobic interaction chromatography for viral clearance |
CN111991571B (en) * | 2020-08-12 | 2022-04-05 | 湖州师范学院 | Method for inactivating viruses with low pH value on column |
CA3198684A1 (en) * | 2020-10-30 | 2022-05-05 | Genentech, Inc. | Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate |
CN113880908B (en) * | 2021-08-25 | 2024-05-14 | 北京伟德杰生物科技有限公司 | Method for purifying fusion protein of recombinant human serum albumin |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5045468A (en) | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
SU1484094A1 (en) * | 1987-04-03 | 1994-01-15 | Институт биоорганической химии АН БССР | Method of purification of antibodies raised to thyroid hormones |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
EP0666312A1 (en) | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
US5853714A (en) | 1995-03-27 | 1998-12-29 | Genetics Institute, Inc. | Method for purification of IL-12 |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JP4306813B2 (en) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | New method for culturing animal cells |
PT802257E (en) | 1996-04-19 | 2003-01-31 | Nestle Sa | IMMORTALIZED LINE OF HUMAN COLON EPITHELIAL CELLS |
WO1998017786A1 (en) | 1996-10-23 | 1998-04-30 | Oravax, Inc. | Heat inactivation of viruses in antibody preparations |
EP0936923B1 (en) | 1996-11-15 | 2003-12-17 | Kennedy Institute Of Rheumatology | SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY |
ES2335365T3 (en) | 1996-11-27 | 2010-03-25 | Genentech, Inc. | PURIFICATION FOR POLYPEPTIDE AFFINITY IN A PROTEIN MATRIX A. |
US6955917B2 (en) | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
IL121900A (en) | 1997-10-07 | 2001-12-23 | Omrix Biopharmaceuticals Ltd | Method for the purification of immunoglobulins |
US20020045207A1 (en) | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
WO1999032605A1 (en) | 1997-12-19 | 1999-07-01 | Novo Nordisk A/S | Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents |
DE69907439T3 (en) | 1998-05-06 | 2014-01-02 | Genentech, Inc. | Purification of proteins by ion exchange chromatography |
US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
WO2001023592A2 (en) | 1999-09-27 | 2001-04-05 | Genentech, Inc. | Methods for making recombinant proteins using apoptosis inhibitors |
EP1254216B1 (en) | 2000-02-08 | 2006-06-07 | Genentech, Inc. | Improved galactosylation of recombinant glycoproteins |
KR101111103B1 (en) | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | Antibodies that bind human interleukin-18 and methods of making and using |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
EP1175931A1 (en) | 2000-07-25 | 2002-01-30 | Computer Cell Culture Center S.A. | Integration of high cell density bioreactor operation with ultra fast on-line downstream processing |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US6635448B2 (en) | 2000-08-21 | 2003-10-21 | Clonexdevelopment, Inc. | Methods and compositions for increasing protein yield from a cell culture |
US6693173B2 (en) | 2000-12-26 | 2004-02-17 | Alpha Therapeutic Corporation | Method to remove citrate and aluminum from proteins |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
EP1404428B1 (en) | 2001-06-05 | 2006-07-19 | Genetics Institute, LLC | Methods for purifying highly anionic proteins |
NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
KR20040039472A (en) | 2001-10-02 | 2004-05-10 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Method for production of recombinant proteins in eukaryote cells |
DE60232265D1 (en) | 2001-10-25 | 2009-06-18 | Genentech Inc | GLYCOPROTEIN COMPOSITIONS |
PT2308888T (en) | 2001-11-14 | 2017-05-03 | Janssen Biotech Inc | Anti-il-6 antibodies, compositions, methods and uses |
EP1453948A2 (en) | 2001-11-28 | 2004-09-08 | Sandoz Gmbh | Cell culture process |
ATE425989T1 (en) | 2001-12-21 | 2009-04-15 | Immunex Corp | PROTEIN PURIFICATION PROCESS |
US20030201229A1 (en) | 2002-02-04 | 2003-10-30 | Martin Siwak | Process for prefiltration of a protein solution |
DE60325334D1 (en) | 2002-02-05 | 2009-01-29 | Genentech Inc | PROTEIN PURIFICATION |
CA2417689C (en) | 2002-03-05 | 2006-05-09 | F. Hoffmann-La Roche Ag | Improved methods for growing mammalian cells in vitro |
US20030190710A1 (en) | 2002-03-28 | 2003-10-09 | Devries Ruth L. | Control of glycoforms in IgG |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
JP4510938B2 (en) | 2002-07-15 | 2010-07-28 | イミュネックス・コーポレーション | Method and medium for regulating sialic acid addition of proteins produced by mammalian cells |
US6974681B1 (en) | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
US7067279B1 (en) | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
WO2004026427A2 (en) | 2002-09-17 | 2004-04-01 | Gtc Biotherapeutics, Inc. | Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds |
US7208585B2 (en) | 2002-09-18 | 2007-04-24 | Genencor International, Inc. | Protein purification |
US20040162414A1 (en) | 2002-11-22 | 2004-08-19 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
BR0317723A (en) | 2002-12-23 | 2005-11-22 | Bristol Myers Squibb Co | Mammalian cell culture process for protein production |
US7332303B2 (en) | 2002-12-23 | 2008-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
JPWO2004087761A1 (en) * | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | Purification of human monoclonal antibodies and human polyclonal antibodies |
DK1623019T4 (en) | 2003-05-15 | 2017-03-27 | Wyeth Llc | LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE |
PL1648940T3 (en) | 2003-07-28 | 2016-12-30 | Reducing protein a leaching during protein a affinity chromatography | |
GB2404665B (en) | 2003-08-08 | 2005-07-06 | Cambridge Antibody Tech | Cell culture |
JP4740138B2 (en) | 2003-10-10 | 2011-08-03 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Method for large-scale production of polypeptides in eukaryotic cells and culture vessels suitable therefor |
PT2336172E (en) | 2003-10-27 | 2015-02-20 | Wyeth Llc | Removal of high molecular weight aggregates using hydroxyapatite chromatography |
US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
SE0400886D0 (en) | 2004-04-02 | 2004-04-02 | Amersham Biosciences Ab | Process of purification |
US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
DE602005019038D1 (en) | 2004-05-04 | 2010-03-11 | Novo Nordisk Healthcare Ag | O-LINKED GLYCO FORMS OF FACTOR VII AND METHOD FOR THE PRODUCTION THEREOF |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
CA2579845C (en) | 2004-09-30 | 2014-11-18 | Jens Vogel | Devices and methods for integrated continuous manufacturing of biological molecules |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
JP2006143601A (en) | 2004-11-16 | 2006-06-08 | Yamato Yakuhin Kk | Blood viscosity-reducing agent |
US8728828B2 (en) | 2004-12-22 | 2014-05-20 | Ge Healthcare Bio-Sciences Ab | Purification of immunoglobulins |
US8530192B2 (en) | 2005-02-11 | 2013-09-10 | Novo Nordisk Healthcare Ag | Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate |
KR101482791B1 (en) | 2005-03-11 | 2015-01-21 | 와이어쓰 엘엘씨 | A method of weak partitioning chromatography |
MX2007012499A (en) | 2005-04-11 | 2007-12-06 | Medarex Inc | Protein purification using hcic amd ion exchange chromatography. |
WO2006113743A2 (en) | 2005-04-18 | 2006-10-26 | Massachusetts Institute Of Technology | Compositions and methods for rna interference with sialidase expression and uses thereof |
US7247457B2 (en) | 2005-04-26 | 2007-07-24 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein |
JP2008541770A (en) | 2005-06-03 | 2008-11-27 | ジェネンテック・インコーポレーテッド | Methods for producing antibodies having altered fucosylation levels |
JP2008543839A (en) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | Self-buffering protein formulation |
BRPI0611600B8 (en) | 2005-06-17 | 2021-05-25 | Wyeth Corp | method for purifying a protein having an fc region from a source liquid comprising the protein and one or more impurities, and kit |
WO2007022799A1 (en) | 2005-08-26 | 2007-03-01 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
AR058140A1 (en) | 2005-10-24 | 2008-01-23 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
EP3026109B1 (en) | 2005-12-08 | 2022-03-09 | Amgen Inc. | Improved production of glycoproteins using manganese |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
SG10201406358SA (en) * | 2006-04-05 | 2014-12-30 | Abbvie Biotechnology Ltd | Antibody purification |
EP2032600A2 (en) | 2006-05-19 | 2009-03-11 | Glycofi, Inc. | Erythropoietin compositions |
EP2069387A4 (en) | 2006-06-14 | 2011-02-02 | Glaxosmithkline Llc | Methods for purifying antibodies using ceramic hydroxyapatite |
JP5401310B2 (en) | 2006-07-13 | 2014-01-29 | ワイス・エルエルシー | Glycoprotein production |
WO2008025748A1 (en) * | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
US7714111B2 (en) | 2006-09-08 | 2010-05-11 | Wyeth Llc | Arginine derivative wash in protein purification using affinity chromatography |
US10982250B2 (en) | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
US20110105734A1 (en) | 2006-12-06 | 2011-05-05 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human erythropoietin |
WO2008079280A1 (en) * | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
PT2115126E (en) | 2007-03-02 | 2015-08-24 | Wyeth Llc | Use of copper and glutamate in cell culture for production of polypeptides |
EP2077859A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | Antibody formulation |
DK2508612T3 (en) | 2007-04-03 | 2018-01-22 | Oxyrane Uk Ltd | Glycosylation of molecules |
BRPI0810471A2 (en) | 2007-04-16 | 2014-11-11 | Momenta Pharmaceuticals Inc | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS |
TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
WO2008135498A2 (en) | 2007-05-04 | 2008-11-13 | Novo Nordisk A/S | Prevention of protein degradation in mammalian cell cultures |
EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
US20100291065A1 (en) * | 2007-05-11 | 2010-11-18 | Kabanov Alexander V | Compositions for Protein Delivery and Methods of Use Thereof |
WO2008141207A1 (en) | 2007-05-11 | 2008-11-20 | Amgen Inc. | Improved feed media |
WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
EP4335863A2 (en) | 2007-07-09 | 2024-03-13 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
US20090042253A1 (en) | 2007-08-09 | 2009-02-12 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
WO2009058769A1 (en) | 2007-10-30 | 2009-05-07 | Schering Corporation | Purification of antibodies containing hydrophobic variants |
SI2840090T1 (en) * | 2007-10-30 | 2018-05-31 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
MX343269B (en) | 2007-12-27 | 2016-10-31 | Baxter Int | Cell culture processes. |
US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
EP2271669A1 (en) | 2008-03-11 | 2011-01-12 | Genentech, Inc. | Antibodies with enhanced adcc function |
EP2271382B1 (en) | 2008-04-15 | 2013-03-13 | Grifols Therapeutics Inc. | Two-stage ultrafiltration/diafiltration |
JP5624535B2 (en) | 2008-05-02 | 2014-11-12 | シアトル ジェネティクス,インコーポレーテッド | Methods and compositions for preparing antibodies and antibody derivatives having low core fucosylation |
US8318416B2 (en) | 2008-08-08 | 2012-11-27 | Biogen Idec Ma Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
MX2011001506A (en) | 2008-08-14 | 2011-03-15 | Genentech Inc | Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography. |
WO2010036443A1 (en) | 2008-09-26 | 2010-04-01 | Eureka Therapeutics, Inc. | Cell lines and proteins with variant glycosylation pattern |
CA2739455A1 (en) | 2008-10-20 | 2010-04-29 | Abbott Laboratories | Antibodies that bind to il-12 and methods of purifying the same |
TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
NZ592094A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Antibodies that bind to il-18 and methods of purifying the same |
ES2535734T3 (en) | 2008-10-20 | 2015-05-14 | Abbvie Inc. | Isolation and purification of antibodies by affinity chromatography with protein A |
JP5793080B2 (en) | 2008-10-31 | 2015-10-14 | ワイス・エルエルシー | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
JP2012511531A (en) | 2008-12-09 | 2012-05-24 | エフ.ホフマン−ラ ロシュ アーゲー | Method for obtaining an excipient-free antibody solution |
ES2488542T3 (en) | 2008-12-22 | 2014-08-27 | F. Hoffmann-La Roche Ag | Immunoglobulin purification |
CA2748807C (en) | 2009-01-08 | 2019-01-29 | Ge Healthcare Bio-Sciences Ab | Separation method using single polymer phase systems |
CA2752393C (en) | 2009-03-05 | 2020-01-14 | Biogen Idec Ma Inc. | Purification of immunoglobulins |
ES2573663T5 (en) | 2009-03-27 | 2019-12-12 | Asahi Kasei Medical Co Ltd | Procedure for removing viruses from a solution of high concentration monoclonal antibodies |
US8063189B2 (en) | 2009-04-13 | 2011-11-22 | Bristol-Myers Squibb Company | Protein purification by citrate precipitation |
EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
WO2010136515A1 (en) | 2009-05-28 | 2010-12-02 | Boehringer Ingelheim International Gmbh | Method for a rational cell culturing process |
CA2763164A1 (en) | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
EP3643773A1 (en) | 2009-07-06 | 2020-04-29 | F. Hoffmann-La Roche AG | Method of culturing eukaryotic cells |
WO2011009623A1 (en) | 2009-07-24 | 2011-01-27 | F. Hoffmann-La Roche Ag | Optimizing the production of antibodies |
WO2011015926A1 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
RU2573894C2 (en) | 2009-08-06 | 2016-01-27 | Дженентек, Инк. | Method for improving process of elimination of viruses in protein purification |
US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
WO2011024025A1 (en) | 2009-08-28 | 2011-03-03 | Avesthagen Limited | An erythropoietin analogue and a method thereof |
CN108409829A (en) | 2009-09-01 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | The protein purification enhanced by improved A albumen wash-outs |
US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
EP2490780A4 (en) | 2009-10-20 | 2014-04-09 | Merck Sharp & Dohme | Use of mixed mode chromatography for the capture and purification of basic antibody products |
EP3037104B1 (en) | 2009-10-20 | 2020-05-27 | AbbVie Inc. | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
US9096879B2 (en) | 2009-11-24 | 2015-08-04 | Biogen Ma Inc. | Method of supplementing culture media to prevent undesirable amino acid substitutions |
US20110136682A1 (en) | 2009-12-04 | 2011-06-09 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
US8277649B2 (en) | 2009-12-14 | 2012-10-02 | General Electric Company | Membranes and associated methods for purification of antibodies |
EP2513134B1 (en) | 2009-12-18 | 2017-09-06 | Novartis AG | Wash solution and method for affinity chromatography |
KR101405463B1 (en) | 2010-01-15 | 2014-06-27 | 그래핀스퀘어 주식회사 | Graphene protective film for preventing gas and water, method of forming the same and uses of the same |
AU2011237695B2 (en) | 2010-04-06 | 2015-10-15 | Heliae Development, Llc | Sequential solvent extraction of oil and proteinaceous material from oleaginous material by using solvents of decreasing polarity |
CA2794697A1 (en) | 2010-04-07 | 2011-10-13 | Momenta Pharmaceuticals, Inc. | High mannose glycans |
PT2563904E (en) | 2010-04-26 | 2015-05-12 | Novartis Ag | Improved cell culture medium |
LT2563906T (en) | 2010-04-26 | 2018-02-26 | Novartis Ag | Process for cultivation of cho cells |
KR20190067277A (en) | 2010-05-28 | 2019-06-14 | 제넨테크, 인크. | Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression |
WO2012019160A1 (en) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Dipeptides to enhance yield and viability from cell cultures |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
KR101898302B1 (en) | 2010-10-15 | 2018-09-13 | 제이씨알 파마 가부시키가이샤 | Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain |
EP2450375A1 (en) | 2010-11-09 | 2012-05-09 | Sandoz Gmbh | Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor |
WO2012078376A1 (en) | 2010-12-08 | 2012-06-14 | Amgen Inc. | Ion exchange chromatography in the presence of an amino acid |
WO2012084829A1 (en) | 2010-12-21 | 2012-06-28 | F. Hoffmann-La Roche Ag | Isoform enriched antibody preparation and method for obtaining it |
MX346663B (en) | 2011-03-06 | 2017-03-27 | Merck Serono Sa | Low fucose cell lines and uses thereof. |
CA2830640A1 (en) | 2011-03-25 | 2012-10-04 | Genentech, Inc. | Novel protein purification methods |
EP2511293A1 (en) | 2011-04-13 | 2012-10-17 | LEK Pharmaceuticals d.d. | A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins |
WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
RU2592680C2 (en) | 2011-04-29 | 2016-07-27 | Биокон Рисерч Лимитед | Method for reduction of accumulation of lactate during culturing and method of producing antibody |
US20120283419A1 (en) | 2011-05-03 | 2012-11-08 | Avantor Performance Materials, Inc. | Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties |
US9562252B2 (en) | 2011-05-13 | 2017-02-07 | Biogen Ma Inc. | Methods of preventing and removing trisulfide bonds |
WO2013006461A1 (en) | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Cholesterol-based media supplementals for cell culture |
SI2837680T1 (en) | 2011-07-01 | 2020-07-31 | Amgen Inc. | Mammalian cell culture |
CN103717729B (en) | 2011-07-08 | 2017-11-21 | 动量制药公司 | Cell culture processes |
WO2013013013A2 (en) | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
MX355048B (en) | 2011-10-19 | 2018-04-03 | Roche Glycart Ag | Separation method for fucosylated antibodies. |
-
2009
- 2009-10-20 TW TW098135686A patent/TW201028433A/en unknown
- 2009-10-20 CN CN2009801513952A patent/CN102257005A/en active Pending
- 2009-10-20 BR BRPI0920572A patent/BRPI0920572A8/en active Search and Examination
- 2009-10-20 EP EP09752562A patent/EP2346897A2/en not_active Ceased
- 2009-10-20 JP JP2011532335A patent/JP5856845B2/en active Active
- 2009-10-20 AU AU2009307737A patent/AU2009307737B2/en active Active
- 2009-10-20 WO PCT/US2009/061338 patent/WO2010048192A2/en active Application Filing
- 2009-10-20 KR KR1020117011273A patent/KR101722423B1/en active IP Right Grant
- 2009-10-20 SG SG10201702951RA patent/SG10201702951RA/en unknown
- 2009-10-20 NZ NZ592097A patent/NZ592097A/en unknown
- 2009-10-20 CA CA2738499A patent/CA2738499A1/en not_active Abandoned
- 2009-10-20 US US12/582,556 patent/US9109010B2/en active Active
- 2009-10-20 RU RU2011120174/10A patent/RU2551237C2/en active
- 2009-10-20 MX MX2011004201A patent/MX2011004201A/en active IP Right Grant
- 2009-10-20 SG SG2013077995A patent/SG195577A1/en unknown
- 2009-10-20 CN CN201510353605.3A patent/CN104974251A/en active Pending
-
2011
- 2011-03-24 IL IL211917A patent/IL211917A0/en unknown
- 2011-04-06 ZA ZA2011/02552A patent/ZA201102552B/en unknown
-
2014
- 2014-10-01 JP JP2014203181A patent/JP6023140B2/en active Active
-
2015
- 2015-08-17 US US14/828,072 patent/US20150344564A1/en not_active Abandoned
-
2016
- 2016-04-13 JP JP2016080187A patent/JP2016193900A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2009307737B2 (en) | 2015-07-23 |
ZA201102552B (en) | 2012-01-25 |
RU2551237C2 (en) | 2015-05-20 |
US9109010B2 (en) | 2015-08-18 |
US20150344564A1 (en) | 2015-12-03 |
JP6023140B2 (en) | 2016-11-09 |
JP2015051975A (en) | 2015-03-19 |
JP5856845B2 (en) | 2016-02-10 |
WO2010048192A3 (en) | 2010-06-24 |
RU2011120174A (en) | 2012-11-27 |
CN102257005A (en) | 2011-11-23 |
BRPI0920572A8 (en) | 2015-10-27 |
TW201028433A (en) | 2010-08-01 |
AU2009307737A1 (en) | 2010-04-29 |
IL211917A0 (en) | 2011-06-30 |
CA2738499A1 (en) | 2010-04-29 |
BRPI0920572A2 (en) | 2015-09-29 |
EP2346897A2 (en) | 2011-07-27 |
US20100136025A1 (en) | 2010-06-03 |
JP2012506385A (en) | 2012-03-15 |
SG195577A1 (en) | 2013-12-30 |
JP2016193900A (en) | 2016-11-17 |
MX2011004201A (en) | 2011-05-24 |
NZ592097A (en) | 2013-01-25 |
WO2010048192A2 (en) | 2010-04-29 |
KR20110086069A (en) | 2011-07-27 |
CN104974251A (en) | 2015-10-14 |
KR101722423B1 (en) | 2017-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201102552B (en) | Viral inactivation during purification of antibodies | |
EP2334328A4 (en) | Methods for purification of viruses | |
HK1225316A1 (en) | Methods of treating viral infections | |
EP2291388A4 (en) | Process for purification of antibodies | |
PL3192874T3 (en) | Virus purification | |
EP2254597A4 (en) | Methods of treatment using anti-mif antibodies | |
IL212709A0 (en) | Arginine inactivation of viruses | |
EP2493479A4 (en) | Methods of treating viral associated diseases | |
IL214434A0 (en) | Purification of immunoglobulins | |
EP2265129A4 (en) | Chromatography purification of antibodies | |
IL226926B (en) | Viral inactivation using improved solvent-detergent method | |
HK1144794A1 (en) | Devices for treatment of viral infections | |
PT2417251E (en) | Method for purifying the rabies virus | |
GB0922623D0 (en) | Methods for the purification of cucurbituril | |
EP2519537A4 (en) | Purification of proteins | |
EP2432885A4 (en) | Methods for enhancing infectivity of retroviruses | |
IL205035A0 (en) | Methods of inhibiting viral infection | |
IL204940A0 (en) | Methods of inhibiting viral infection | |
GB2459738B (en) | Method of purification | |
EP2452196A4 (en) | Purification of monoclonal antibodies | |
IL188628A0 (en) | Use of soluble ldl-r for viral hepatitis | |
GB0803779D0 (en) | Viral inactivation process | |
GB0811276D0 (en) | Viral inactivation process | |
GB0815069D0 (en) | Viral inactivation | |
GB0813716D0 (en) | Treatment of viral infection |